Acousia Therapeutics GmbH, a clinical-stage biotechnology company pioneering treatments for acute and chronic inner ear hearing loss, today announced positive top-line efficacy results from its
Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its
The German Society of Urology (Deutsche Gesellschaft für Urology, DGU) has highlighted Acousia’s PROHEAR Study as their Study of the Month, acknowledging the urgent need
Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN:
The PROHEAR study is a placebo-controlled Phase 2a study with split-body design investigating the otoprotective efficacy of ACOU085 in patients with testicular cancer undergoing high-dose,
Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first
German pioneer biotech accelerates hearing loss solution development with fresh capital boost Acousia Therapeutics GmbH, a clinical-stage biotech company developing drug candidates against acute and
Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms
Acousia Therapeutics GmbH to share key learnings and data from its lead candidate development programs — clinical stage ACOU085 and late preclinical stage ACOU082 —
